Alumis Inc. (NASDAQ:ALMS) Given Average Recommendation of “Buy” by Brokerages

Alumis Inc. (NASDAQ:ALMS) has been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $26.83.

A number of research firms have recently weighed in on ALMS. Robert W. Baird began coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Alumis in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Finally, Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st.

Alumis Trading Up 1.7 %

NASDAQ ALMS opened at $6.68 on Friday. Alumis has a 1-year low of $6.40 and a 1-year high of $13.53. The company has a 50 day moving average of $8.33 and a 200-day moving average of $10.56.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ALMS. Millennium Management LLC acquired a new position in Alumis during the second quarter valued at approximately $3,376,000. Maven Securities LTD acquired a new position in Alumis during the second quarter valued at approximately $332,000. Towerview LLC grew its stake in shares of Alumis by 22.6% during the third quarter. Towerview LLC now owns 380,000 shares of the company’s stock worth $4,058,000 after buying an additional 70,000 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in shares of Alumis during the third quarter worth $1,160,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Alumis during the third quarter worth $27,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.